Guggenheim Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $38

Benzinga Newsdesk www.benzinga.com Neutral 55.8%

Neg 0% Neu 55.8% Pos 0%

Guggenheim analyst Brad Canino maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $40 to $38.